Drug combination for advanced breast cancer with type 2 diabetes
Treatments studied
Part of Cancer, Hormones & metabolism, Skin clinical trials.
This trial combines two or three drugs (inavolisib, fulvestrant, and sometimes palbociclib) to treat hormone receptor positive, HER2 negative advanced breast cancer that has a PIK3CA mutation. The goal is to find out if this combination is safe and effective for people who also have type 2 diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes with average blood sugar (HbA1c) 8% or lower and fasting blood sugar under 185 mg/dL, unless you use short-term insulin.
- This is for advanced breast cancer (cancer that has spread or can't be removed) that is hormone receptor positive and HER2 negative.
- Your tumor must have a specific PIK3CA mutation (this is checked by a test).
- You have not had any previous treatment for advanced breast cancer.
- You have measurable disease (tumors that can be seen on scans).
- You are healthy enough for light activity (ECOG 0 or 1) and have adequate blood counts and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new targeted pill (inavolisib) plus hormone therapy (fulvestrant) can slow or stop breast cancer growth in people whose cancer has a specific genetic change called a PIK3CA mutation. It is for patients whose disease worsened after previous hormone-and-CDK-inhibitor treatment.
This trial tests whether a new drug combo (inavolisib plus fulvestrant) works better than an existing one (alpelisib plus fulvestrant) for people with a specific type of advanced breast cancer that has a PIK3CA mutation. It aims to find a treatment that may help control the cancer longer.
This trial tests a combination of three targeted therapies (inavolisib, ribociclib, and fulvestrant) in people with a specific type of advanced breast cancer that has a PIK3CA genetic change. The goal is to see if this new combination can shrink tumors or slow cancer growth, potentially offering a new option before other treatments are needed.
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
This study looks at how well a drug called inavolisib works when combined with hormone therapy for people with a certain type of advanced breast cancer that has a specific gene change (PIK3CA). It aims to see if this treatment helps control the cancer in real-world settings.
This trial tests a combination of three drugs (inavolisib, ribociclib, and fulvestrant) compared to a placebo plus two of the drugs (ribociclib and fulvestrant) for people with advanced hormone receptor-positive breast cancer who have not had prior treatment for advanced disease. The goal is to see if adding inavolisib improves outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.